Previous studies using classical cytogenetics have demonstrated the presence of the t(11;14) (q13;q32) chromosomal translocation in some cases of lymphocytic lymphoma of intermediate differentiation (IDL), a distinct type of low grade B-cell lymphoma. This finding suggested that the bckl region (located at band q13 of chromosome 1 1 ) might be involved in this neoplasm. Using a genomic probe from the major breakpoint area of the bckl locus, we identified rearrangements of the bcl-I region in 10 of 19 cases, 2 of which comigrated with a rearranged allele of the immunoglobulin heavy chain gene joining region. In contrast, bckl rearrangements were not found in other types of low grade B-cell lymphoma, specifically in 36 cases of chronic lymphocytic leukemia/small lymphocytic lym-ONRANDOM chromosomal translocations are linked N with distinct subtypes of non-Hodgkin's lymphomas.
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For example, translocations involving chromosome 8q24 and the immunoglobulin heavy or light chain loci have been found in the majority of cases of Burkitt's lymphoma.'.' Similarly, the t( 14;18) (q32;q21) translocation occurs in 80% to 90% of follicular lymphoma^.^.^ In both instances the translocation juxtaposes a cellular proto-oncogene, c-myc at 8q24 and bcl-2 at 18q21, to an immunoglobulin gene with subsequent deregulation of protein synthesis and cell pr~liferation.~.~ The t( 11;14) (q13;q32) translocation has been identified sporadically in cases of low grade B-cell leukemia and lymphoma.' Tsujimoto et aI6 cloned the region of chromosome 11 involved in the translocation and designated it as bcl-1. To date, a gene product associated with the translocated chromosome 11 has not been found! Nevertheless, probes derived from the bcl-1 region of chromosome 1 1 have occasionally identified rearrangements of this locus in B-cell leukemias and lymphomas6-" and are particularly useful diagnostically because Southern blot analysis has been shown to be an acceptable and more convenient method than classical cytogenetics for demonstrating the presence of chromosomal trans location^.^ 
MATERIALS AND METHODS
Nineteen cases of IDL with available frozen cell suspensions or tissue blocks were analyzed. Each case was classified without knowledge of the molecular results using histologic criteria previously de~cribed.'~.'~ Other well characterized low grade B-cell lymphomas including 36 cases of CLL/SLL and 27 cases of FL (8 small cleaved cell type and 19 mixed small cleaved and large cell type) were also selected as control groups with which to compare the prevalence of bcl-1 rearrangements in IDL. The prevalence of bcl-2 rearrangements in each subtype of low grade lymphoma was also compared.
Eighteen of the 19 IDLs were immunophenotyped as a part of their initial diagnostic workup by various methods previously described2' including frozen section immunohistochemistry (13 cases) and cell suspensions studied by flow cytometry (12 cases). Although the panel of antibodies varied from case to case, in all lesions the following panel of reagents was used: immunoglobulin heavy (mu, delta, gamma, alpha) and light (kappa, lambda) chains (either Bethesda Research Laboratories, Bethesda, MD, or Tag0 Laboratories, Burlingame, CA), B1 (CD20), B4 (CD19), CALLA (CDlO), TI1 (CD2) (Coulter Monoclonal Antibodies, Hialeah, FL), Leu1 (CD5), and Leu4 (CD3) (BectonDickinson, Mountain View, CA).
Frozen tissue or cell suspensions were Immunophenotypic methods. thawed and high molecular weight DNA was obtained by standard proteinase K/RNAse phenol-chloroform extraction. Following purification, 15 to 20 micrograms of DNA were completely digested with the EcoRI, HindIII, and BamHI restriction enzymes according to the conditions recommended by the supplier (Bethesda Research Laboratories, Bethesda, MD). The digested DNA was electrophoresed through 0.7% agarose gels, depurinated with 0.25N HCl, and denatured and transferred in 0.4N NaOHZ5 onto a nylon membrane (Genescreen Plus, New England Nuclear Research Products, Boston, MA). The membranes were hybridized and washed in high stringency conditions as described previously?6 Cloned genomic DNA probes were radiolabeled with P3' using the random primer method.*' The probes used have been previously de~cribed.~.~.'~ The immunoglobulin heavy chain gene was assessed with a BglII-BglII, 3 .8 kb fragment cloned from the joining (Jh) region (courtesy of Dr P. Leder). The bcl-1 region of chromosome 11 was studied using a Sstl-Sstl, 2.0 kb fragment (probe "b" in reference 6) (gift of Dr Y. Tsujimoto). The bcl-2 region of chromosome 18 was analyzed with three probes: a HindIII-EcoRI, 2.8 kb fragment cloned from the major breakpoint region (mbr), an EcoRI-EcoRI, 4.0 kb fragment encompassing the minor breakpoint cluster region (mcr) (probe "pfl-2" of reference 4), and a BamHIBamHI, 0.4 kb fragment 12 kb 3' to the major breakpoint region (near, but not identical with the probe "c" in reference 3). (The major and minor breakpoint region probes were gifts from Dr Y. Tsujimoto and Dr M. Cleary, respectively.)
Molecular techniques.

RESULTS
The clinical features of patients with IDL have been previously r e p~r t e d . '~ In this study, the median age of the patients was 59 years (range, 32 to 78). There were 14 men and 5 women. All patients presented with clinical stage 111 (6 patients) or IV (13 patients) disease. Twelve received various chemotherapy regimens, six were observed without therapy, and in one case the details of treatment are unknown. Clinical follow-up was available for 16 patients (median, 13 months). Six patients have died of disease.
Zmmunophenotypicjindings. All 18 cases immunophenotyped demonstrated a monoclonal B-cell population. All cases expressed IgM (10 lambda, 8 kappa) and 11 lesions were also IgD positive. All cases expressed at least one pan-B-cell antigen (CDl9 and/or CD20), 16 of 18 were CD5 positive, 6 of 15 expressed CDlO antigen, and all were negative for the pan-T-cell antigens CD2 and CD3.
In all IDLs the immunoglobulin heavy chain gene was rearranged demonstrating the presence of tumor DNA in each sample of extracted DNA. In 16 cases two rearrangements and in 3 cases one rearrangement were identified with the JH probe.
Ten of 19 IDLs had a single rearrangement of the bcl-1 region; nine of 18 IDLs using the described bcl-1 probe and one additional case, detected previously and reported separately6 (Table 1 ). In 8 of the 10 cases with bcl-1 rearrangements, the rearrangements were detected with more than one restriction enzyme (BamHI, EcoRI, and/or HindII) (Fig 1A) . In 2 additional IDLs a bel-1 rearrangement was detected with only one restriction enzyme, that enzyme being BamHI in each case (Fig IB) . This finding suggests that the breakpoint on chromosome 11 is likely to occur within the 3.0 kb germline HindIII fragment (Fig 1C) . In the two cases which showed bcl-1 rearrangements with Clinical data.
Genotypic results. only BamHI-digested DNA, the results suggest that the breakpoints occurred between the 5' BumHI and HindIII restriction enzyme sites. Although the rearrangement pattern is also compatible with a break between the 3' EcoRI and BamHT restriction enzyme sites, in both cases the sizes of the rearranged fragments (1 6 to 17 kb) are smaller than the smallest theoretical size expected from a rearrangement occurring in this region. (The distance from the 5' BamHI site to the 3' EcoRI site is 19 kb.) Thus, we infer that the breakpoints are 5'. In addition, the rearranged fragments in each case were of similar size (Fig 1B) suggesting that the breakpoints on chromosome 11 (as well as on chromosome 14) are clustered.
ND
In each case with a bc1-1 rearrangement, two rearrangements of the immunoglobulin heavy chain gene were identified. In two cases, the rearranged bcl-1 fragment (present in all DNA digests) comigrated with one of the rearranged fragments detected with the Jh probe indicative of the t(l1;14) (q13;q32) translocation.
Using the bcl-1 probe no rearrangements were detected in 36 cases of CLL/SLL or in 27 cases of FL (data not shown).
Eighteen IDLs were also analyzed with three probes derived from the bcl-2 region of chromosome 18. Rearrangements of the bcl-2 region were not detected in any case of IDL. Similarly, bcl-2 rearrangements were not found in the 36 cases of CLL/SLL. In contrast, 21 of the 27 cases of FL had unequivocal rearrangements of the bcl-2 region, the majority of which comigrated with rearrangements of the immunoglobulin heavy chain gene, showing evidence of the t(14;18) (q32;q21) translocation (data not shown).
Lack of correlation of bcl-1 results with clinical and immunophenotypic data. There were no clinical differences between patients with bcl-1 rearranged lymphomas For IN IDL   2089 and unrearranged lymphomas. In particular, the percentage of patients treated was approximately the same, and response to therapy and survival were similar. Four of 9 patients (1 lost to follow-up) whose tumors had bcl-1 rearrangements died of disease compared with two of seven (two lost to follow-up) cases without bcl-1 rearrangements. Similarly, there were no significant immunophenotypic differences between the neoplasms with bel-1 rearrangements and the IDLs without bcl-1 rearrangements (data not shown).
DISCUSSION
These results demonstrate the presence of bcl-1 rearrangements in 10 of 19 (53%) cases of IDL using a probe cloned from the bcl-1 region of chromosome 1 1 . In contrast, rearrangements of the bcl-1 locus were not found in 36 cases of CLL/SLL or 27 cases of FL. These findings suggest a role for the bcl-1 region of chromosome 1 1 in the pathogenesis of IDL.
We speculate that, similar to the mechanisms of activation of both bcl-2 and c-mycin the t(14;lS) (q32;q21) and t(8;14) (q24;q32) translocations, respectively, translocation of the bcl-1 region to the immunoglobulin gene locus activates a postulated proto-oncogene leading to unregulated cell growth. Alternatively, rearrangement of the bcl-1 region may induce lymphomagenesis by other, as yet unknown, mechanisms.
The 53% prevalence of bcl-1 rearrangements in IDLs reported here may, in fact, underestimate the true incidence. Our own data suggest the presence of at least two breakpoint clusters detected with the bcl-1 probe; one breakpoint within the 3.0 kb Hind111 germline fragment and one breakpoint farther 5', between the 5' BamHI site and the 3.0 kb Hind111 germline fragment. Other breakpoints farther 5' in the bcf-1 region have been reported,"" and these breakpoints would not be detected with the probe we used. Furthermore, additional breakpoints, as yet unreported, may exist.
We did not find bcl-1 rearrangements in 36 cases of CLL/SLL in this study. Although bcl-1 rearrangement was first detected in a case reported as CLL,28 our review of the literature indicates that bcl-1 rearrangements are uncommon in cases of CLL/SLL. Combining our own data with those of three large survey s t~d i e s , ' .~*~~ bcf-1 rearrangements have been identified in only 6 of 163 unselected cases (3%) of CLL/SLL. There are 4 additional cases of bcl-1 rearrangement in CLL/SLL,6s83" but these were specifically selected for the t( 11;14) chromosomal translocation, and to include them in prevalence reporting would bias the true prevalence. Also, occasional cases reported in the literature as CLL/SLL may, in fact, be examples of IDL. For example, Ince et ai9 describe one of their two cases of SLL as being a mantle-zone variant. The mantle-zone pattern is a morphologic feature that is characteristic of IDL. In addition, in the leukemic phase IDL may be difficult to distinguish from CLL/SLL without a lymph node biopsy. 30 There have not been other studies that have specifically looked for bcl-1 involvement in a series of IDL. However, of the 9 reported cases of leukemias and lymphomas other than CLL/SLL with bel-1 rearrangement~,6.'.~-'' it is possible that 4 cases may be IDLs. Athan et al' have found bel-1 rearrangements in 2 cases of diffuse small cleaved cell lymphoma. IDL is usually best classified as diffuse small cleaved cell lymphoma in the Working Formulation. In addition, Koduru et all0 described bcl-1 rearrangements in 2 cases of "nodular poorly differentiated lymphocytic lymphoma." Bcl-1 rearrangements have not been described in other studies of follicular lymphoma^:^ including this report, and occasional cases of IDL may exhibit a vaguely nodular growth pattern and resemble follicular small cleaved cell lymphoma."
The absence of bcl-2 rearrangements in all cases of IDL studied is of interest. Since 80% to 90% of FLs have bel-2 rearrangements as a result of the t(14;18) (q32;q21) chromosomal translocation: the absence of bcl-2 rearrangements in IDL suggests that IDL is not related to FL and that the molecular mechanisms involved in the pathogenesis of IDL and FL are distinct and unrelated.
In summary, we have identified bcl-1 rearrangements in a high percentage of IDLs, which suggests that this locus may be involved in the pathogenesis of IDL.
